Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

23,924 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Essential role of the histone lysine demethylase KDM4A in the biology of malignant pleural mesothelioma (MPM).
Lapidot M, Case AE, Weisberg EL, Meng C, Walker SR, Garg S, Ni W, Podar K, Hung YP, Carrasco RD, Knott A, Gokhale PC, Sharma S, Pozhitkov A, Kulkarni P, Frank DA, Salgia R, Griffin JD, Saladi SV, Bueno R, Sattler M. Lapidot M, et al. Among authors: sharma s. Br J Cancer. 2021 Aug;125(4):582-592. doi: 10.1038/s41416-021-01441-7. Epub 2021 Jun 4. Br J Cancer. 2021. PMID: 34088988 Free PMC article.
The Small Molecule BC-2059 Inhibits Wingless/Integrated (Wnt)-Dependent Gene Transcription in Cancer through Disruption of the Transducin β-Like 1-β-Catenin Protein Complex.
Soldi R, Halder TG, Sampson S, Vankayalapati H, Weston A, Thode T, Bhalla KN, Ng S, Rodriguez Del Villar R, Drenner K, Kaadige MR, Horrigan SK, Batra SK, Salgia R, Sharma S. Soldi R, et al. Among authors: sharma s. J Pharmacol Exp Ther. 2021 Aug;378(2):77-86. doi: 10.1124/jpet.121.000634. Epub 2021 May 18. J Pharmacol Exp Ther. 2021. PMID: 34006586
A phase I open-label dose-escalation study of the anti-HER3 monoclonal antibody LJM716 in patients with advanced squamous cell carcinoma of the esophagus or head and neck and HER2-overexpressing breast or gastric cancer.
Reynolds KL, Bedard PL, Lee SH, Lin CC, Tabernero J, Alsina M, Cohen E, Baselga J, Blumenschein G Jr, Graham DM, Garrido-Laguna I, Juric D, Sharma S, Salgia R, Seroutou A, Tian X, Fernandez R, Morozov A, Sheng Q, Ramkumar T, Zubel A, Bang YJ. Reynolds KL, et al. Among authors: sharma s. BMC Cancer. 2017 Sep 12;17(1):646. doi: 10.1186/s12885-017-3641-6. BMC Cancer. 2017. PMID: 28899363 Free PMC article. Clinical Trial.
Ceritinib in ALK-rearranged non-small-cell lung cancer.
Shaw AT, Kim DW, Mehra R, Tan DS, Felip E, Chow LQ, Camidge DR, Vansteenkiste J, Sharma S, De Pas T, Riely GJ, Solomon BJ, Wolf J, Thomas M, Schuler M, Liu G, Santoro A, Lau YY, Goldwasser M, Boral AL, Engelman JA. Shaw AT, et al. Among authors: sharma s. N Engl J Med. 2014 Mar 27;370(13):1189-97. doi: 10.1056/NEJMoa1311107. N Engl J Med. 2014. PMID: 24670165 Free PMC article. Clinical Trial.
Phase I Study Evaluating Glesatinib (MGCD265), An Inhibitor of MET and AXL, in Patients with Non-small Cell Lung Cancer and Other Advanced Solid Tumors.
Kollmannsberger C, Hurwitz H, Bazhenova L, Cho BC, Hong D, Park K, Reckamp KL, Sharma S, Der-Torossian H, Christensen JG, Faltaos D, Potvin D, Tassell V, Chao R, Shapiro GI. Kollmannsberger C, et al. Among authors: sharma s. Target Oncol. 2023 Jan;18(1):105-118. doi: 10.1007/s11523-022-00931-9. Epub 2022 Dec 2. Target Oncol. 2023. PMID: 36459255 Clinical Trial.
The novel reversible LSD1 inhibitor SP-2577 promotes anti-tumor immunity in SWItch/Sucrose-NonFermentable (SWI/SNF) complex mutated ovarian cancer.
Soldi R, Ghosh Halder T, Weston A, Thode T, Drenner K, Lewis R, Kaadige MR, Srivastava S, Daniel Ampanattu S, Rodriguez Del Villar R, Lang J, Vankayalapati H, Weissman B, Trent JM, Hendricks WPD, Sharma S. Soldi R, et al. Among authors: sharma s. PLoS One. 2020 Jul 10;15(7):e0235705. doi: 10.1371/journal.pone.0235705. eCollection 2020. PLoS One. 2020. PMID: 32649682 Free PMC article.
Phase II study of everolimus in patients with metastatic colorectal adenocarcinoma previously treated with bevacizumab-, fluoropyrimidine-, oxaliplatin-, and irinotecan-based regimens.
Ng K, Tabernero J, Hwang J, Bajetta E, Sharma S, Del Prete SA, Arrowsmith ER, Ryan DP, Sedova M, Jin J, Malek K, Fuchs CS. Ng K, et al. Among authors: sharma s. Clin Cancer Res. 2013 Jul 15;19(14):3987-95. doi: 10.1158/1078-0432.CCR-13-0027. Epub 2013 Jun 6. Clin Cancer Res. 2013. PMID: 23743569 Free PMC article. Clinical Trial.
Dose-escalating and pharmacologic study of oxaliplatin in adult cancer patients with impaired hepatic function: a National Cancer Institute Organ Dysfunction Working Group study.
Synold TW, Takimoto CH, Doroshow JH, Gandara D, Mani S, Remick SC, Mulkerin DL, Hamilton A, Sharma S, Ramanathan RK, Lenz HJ, Graham M, Longmate J, Kaufman BM, Ivy P; National Cancer Institute Organ Dysfunction Working Group. Synold TW, et al. Among authors: sharma s. Clin Cancer Res. 2007 Jun 15;13(12):3660-6. doi: 10.1158/1078-0432.CCR-06-2385. Clin Cancer Res. 2007. PMID: 17575231 Clinical Trial.
23,924 results
You have reached the last available page of results. Please see the User Guide for more information.